Source: European Medicines Agency (EU) Revision Year: 2019 Publisher: Regeneron Ireland Designated Activity Company (DAC), Europa House, Harcourt Centre, Harcourt Street, Dublin 2, Ireland
LIBTAYO 350 mg concentrate for solution for infusion.
Pharmaceutical Form |
---|
Concentrate for solution for infusion (sterile concentrate). Clear to slightly opalescent, colourless to pale yellow solution with a pH of 6.0 and osmolality between 300 and 360 mmol/kg. The solution may contain trace amounts of translucent to white particles in a single-use vial. |
One ml of concentrate contains 50 mg of cemiplimab.
Each vial contains 350 mg of cemiplimab in 7 ml of solution.
Cemiplimab is produced by recombinant DNA technology in Chinese hamster ovary (CHO) cell suspension culture.
For the full list of excipients, see section 6.1.
Active Ingredient | Description | |
---|---|---|
Cemiplimab |
Cemiplimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the programmed cell death-1 (PD-1) receptor and blocks its interaction with its ligands PD-L1 and PD-L2. Cemiplimab is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma. |
List of Excipients |
---|
L-histidine |
LIBTAYO is provided in a 10 ml clear Type 1 glass vial, with a grey chlorobutyl stopper with FluroTec coating and seal cap with a flip-off button.
Each carton contains 1 vial.
Regeneron Ireland Designated Activity Company (DAC), Europa House, Harcourt Centre, Harcourt Street, Dublin 2, Ireland
EU/1/19/1376/001
Date of first authorisation: 28 June 2019
Drug | Countries | |
---|---|---|
LIBTAYO | Austria, Brazil, Canada, Cyprus, Estonia, Finland, France, Ireland, Israel, Japan, Lithuania, Netherlands, Poland, Romania, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.